Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The discovery of oncogenes (1)
- The discovery of oncogenes (2)
- Oncogenes have dominant phenotypes
- Recessive cancer genes?
- Retinoblastoma: the "two-hit" hypothesis
- Retinoblastoma: heretitary vs sporadic (1)
- Finding cancer genes
- Positional cloning
- Positional cloning of the RB1 locus (1)
- Positional cloning of the RB1 locus (2)
- Retinoblastoma: hereditary vs sporadic (2)
- Loss of heterozygosity (LOH)
- Mechanisms of LOH
- TSGs link hereditary and sporadic cancers
- Recessive genes, dominant inheritance (1)
- Recessive genes, dominant inheritance (2)
- Compound heterozygosity
- Classic TSGs are highly penetrant
- What do tumor suppressors do?
- RB controls the entry of cells into S-phase (1)
- RB controls the entry of cells into S-phase (2)
- RB1 is inactivated in many cancers
- CDKN2A encodes the CDK inhibitor p16
- Homozygous deletions at chr. 9p21
- An alternative reading frame in CDKN2A
- CDKN2A mutations in FAMMM syndrome
- "Caretaker" genes
- Discovery of p53 - 1979
- LOH at the TP53 locus - 1989
- p53 is inactivated in most cancers
- Most common mutations in TP53
- Mutations disrupt the DNA binding domain
- TP53 mutations in Li-Fraumeni syndrome (1)
- TP53 mutations in Li-Fraumeni syndrome (2)
- p53 is activated in response to DNA damage
- p53 transactivates RNA transcription (1)
- p53 transactivates RNA transcription (2)
- p53 transactivates RNA transcription (3)
- Mutant p53 is stabilized (1)
- Mutant p53 is stabilized (2)
- GOF vs dominant negative effects?
- Summary
- Acknowledgements
Topics Covered
- Oncogenes and their history
- Tumor suppressors genes
- Contrast between oncogenes and tumor suppressor genes
- Tumor suppressor genes and the two-hit hypothesis
- Retinoblastoma and RB1 as a tumor suppressor gene
- p53 as a tumor suppressor gene
- Important tumor suppressors that regulate the cell cycle
- Inherited vs. sporadic cancers
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Bunz, F. (2021, January 31). Tumor suppressor genes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/OYDA9421.Export Citation (RIS)
Publication History
Financial Disclosures
- Fred Bunz is a co-founder and stakeholder in Hunterian Medicine, LLC, and the author of the textbook Principles of Cancer Genetics and receive royalties. He also received research support from NIH/NIGMS and the Emerson Collective.
Other Talks in the Series: The Molecular Basis of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Fred Bunz.
I'm an associate professor of
Radiation Oncology here in the Department of Radiation Oncology and
Molecular Radiation Sciences at
the Sydney Kimmel Comprehensive Cancer Center at
Johns Hopkins School of Medicine in Baltimore, Maryland.
The topic of today's lecture will be tumor suppressor genes.
0:18
In order to appreciate the function and concept of the tumor suppressor gene,
it's necessary to first understand
the properties of oncogenes which were the first type of cancer genes to be discovered.
The idea of a dominantly acting cancer gene first arose at the beginning of
the 20th century from some seminal observations by a virologist named Peyton Rous.
Rous had discovered a distinct form of tumor that would affect guinea hens.
0:49
These tumors were very aggressive.
Rous found that if he ground up the tumors,
pass them through a small pore filter and inject with a filtrate into young hens,
he could recreate and actually serially transmit the tumor,
so the tumor would re-grow in the infected chickens.
This was right around the time shortly after the discovery of viruses,
so Rous inferred that the tumor had been transmitted by a virus.
This was the first experimental evidence that cancers could be
transmitted via dominantly acting genes or genetic elements.
1:28
In subsequent decades, investigators used a variety of strategies to isolate oncogenes,
all of them depending on the dominant phenotypes of activated oncogenes.
In this experiment, normal human DNA would be
sheared and delivered to cells and culture with no effect.
However, when shear DNA from
a cancer cell line would be delivered to cells growing in culture,
a proportion of the cells would grow abnormally
and assume cancer-related phenotypes as shown in this illustration.
Subsequent studies would allow the oncogene from this genomic DNA to be isolated.
So the critical observation here was
oncogenes could be isolated on the basis of their effects on cell growth,
on the basis of their function.